Bictegravir

Bictegravir 구조식 이미지
카스 번호:
1611493-60-7
상품명:
Bictegravir
동의어(영문):
GS-9883;Bitravir;GS-9883-01;Bictegravin;Bictegravir;BNKY010-BC03;BICTEGRAVIR-D5;Bictegravir (GS-9883);Bictegravir (100 mg/mL in DMSO);BICTEGRAVIR;GS-9883;GS 9883;GS9883
CBNumber:
CB63161551
분자식:
C21H18F3N3O5
포뮬러 무게:
449.38
MOL 파일:
1611493-60-7.mol

Bictegravir 속성

녹는점
>130°C (dec.)
끓는 점
682.5±55.0 °C(Predicted)
밀도
1.62±0.1 g/cm3(Predicted)
저장 조건
Sealed in dry,Store in freezer, under -20°C
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
4.50±1.00(Predicted)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고 GHS hazard pictograms
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P271 옥외 또는 환기가 잘 되는 곳에서만 취급하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P302+P352 피부에 묻으면 다량의 물로 씻으시오.
P304+P340 흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P312 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P321 (…) 처치를 하시오.
P332+P313 피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P337+P313 눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.
P403+P233 용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405 밀봉하여 저장하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2 0

Bictegravir C화학적 특성, 용도, 생산

주요 응용

Bictegravir, is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM. Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. Bictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine.

Mechanism of action

This single dose medication inhibits the strand transfer of viral DNA into the human genome, preventing HIV-1 virus replication and propagation 2.
In vitro, bictegravir has shown powerful antiviral activity against HIV-2 and various subtypes of HIV-1. It has shown synergistic effects when combined with other ARVs, including tenofovir alafenamide (TAF), emtricitabine (FTC), and darunavir (DRV) Label. The three components of the first USA approved medication ( trade name: Biktarvy ) are as follows:
Bictegravir: integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme necessary for viral replication. Inhibition of the integrase enzyme prevents the integration of HIV-1 into host DNA, blocking the conversion of the HIV-1 provirus and progression of the virus.
Emtricitabine: FTC, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate intracellularly. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase by competing with the substrate deoxycytidine 5'-triphosphate and by incorporating itself into viral DNA preventing DNA chain elongation.
Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Plasma exposure to TAF leads to leakage into cells and then TAF is intracellularly converted to tenofovir by hydrolysis by cathepsin. Tenofovir is subsequently phosphorylated by cellular kinases to the metabolite tenofovir diphosphate, which is the active form of the drug. Tenofovir diphosphate inhibits HIV-1 replication by incorporating into viral DNA by the HIV reverse transcriptase, resulting in DNA chain-termination. Tenofovir diphosphate also weakly inhibits mammalian DNA polymerases.

Pharmacokinetics

Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Bictegravir (BIC) inhibits HIV-1 virus replication into the human genome. It can be taken once daily without additional dosing. Bictegravir (BIC) inhibits strand transfer of viral DNA into the host genome and thereby prevents HIV-1 replication.

부작용

Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat;
High lactic acid level—muscle pain or cramps, stomach pain, trouble breathing, general discomfort and fatigue;
Infection—fever, chills, cough, or sore throat;
Kidney injury—decrease in the amount of urine, swelling of the ankles, hands, or feet;
Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue;
Diarrhea, Headache, Nausea

Bictegravir 준비 용품 및 원자재

원자재

준비 용품


Bictegravir 공급 업체

글로벌( 163)공급 업체
공급자 전화 이메일 국가 제품 수 이점
BIONNA MEDICINE CO.,LTD
01056380788-8515; +8618518759099
790226113@qq.com China 52 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638
sales@sdperfect.com China 294 58
Hangzhou ICH Biofarm Co., Ltd
+undefined8613073685410
sales@ichemie.com China 985 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21691 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714
fandachem@gmail.com China 9348 55
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
sales@tianpharm.com CHINA 304 58
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830
figo.gao@foxmail.com China 7019 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58

Bictegravir 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved